Company news: Amylin vs. Lilly; CVS Caremark

Share this article:
Amylin was granted a temporary restraining order against Eli Lilly & Co. preventing Lilly from going forward with plans to have the same reps detail both Byetta, which it co-promotes with Amylin, and Boehringer Ingelheim's rival type 2 diabetes drug Tradjenta in the US.

The authors of a study of medication adherence that included researchers from Harvard, Brigham and Women's Hospital and CVS Caremark issued their conclusions, calling for: the development of tools allowing prediction and targeting of patients at-risk for non-adherence and prescription abandonment; adoption of a “pharmacy home” concept to simplify care for patients with complex therapies; individualized counseling by pharmacists and healthcare providers; research on the use of financial and other incentives to encourage adherence; a “personalized medicine” approach for pharmacies through pharmacogenomics or individualized counseling with pharmacists; and the use of social networks to improve adherence through family and friends.  

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions